Sanyou Medical announced that on December 2, 2025, the company signed a “Strategic Cooperation and Distribution Agreement” with Korea's Siji Biotech Co., Ltd., and obtained exclusive and non-transferable distribution rights for Novosis products in mainland China. The authorization period is six years from when the product receives a medical device registration certificate from the China Drug Administration. Novosis is a recombinant human bone morphogenetic protein BMP-2 biomaterial product that can promote new bone formation. This cooperation will enrich the company's product line and improve the layout of the orthopedic biomaterials field, but there is uncertainty about product registration approval and marketing sales, and it is not yet possible to predict the specific impact on performance.

Sanyou Medical announced that on December 2, 2025, the company signed a “Strategic Cooperation and Distribution Agreement” with Korea's Siji Biotech Co., Ltd., and obtained exclusive and non-transferable distribution rights for Novosis products in mainland China. The authorization period is six years from when the product receives a medical device registration certificate from the China Drug Administration. Novosis is a recombinant human bone morphogenetic protein BMP-2 biomaterial product that can promote new bone formation. This cooperation will enrich the company's product line and improve the layout of the orthopedic biomaterials field, but there is uncertainty about product registration approval and marketing sales, and it is not yet possible to predict the specific impact on performance.